Allopurinol, benzbromarone and risk of coronary heart disease in gout patients

A population-based study

Hsiu Chen Lin, Masao Daimon, Ching Hung Wang, Yi Ho, Yow Shieng Uang, Shuo Ju Chiang, Li Hsuan Wang

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background The effect of gout on the risk of developing coronary artery disease (CAD) is uncertain. Some studies have found that gout is a risk factor for acute myocardial infarction. This study examined the changes in risk of CAD in gout patients taking allopurinol and/or benzbromarone, and analyzed the dose-response relationship of both drugs with CAD incidence. Methods The medical records of one million subjects from 2000 to 2011 were provided by the Taiwan National Health Insurance Research Database. Cox proportional hazard ratio was used to compare the risk of CAD in gout patients taking allopurinol or/and benzbromarone with those taking neither drug. Hazard ratios (HR) were adjusted for possible confounding factors, including age, gender, hypertension, hyperlipidemia, diabetes mellitus, chronic kidney disease, and relevant medications. Results Of 8047 gout patients, 1422 were treated with allopurinol (Group A), 4141 with benzbromarone (Group B), and 2484 with both drugs (Group A/B) during the follow-up period. Our results showed the incidence of CAD after adjusting for covariates for Group A, Group B, and Group A/B did not significantly differ from the comparison group. However, after adjustment for covariates in dose-response analyses, treatment with over 270 defined daily doses (DDDs) of allopurinol, and over 360 DDDs of benzbromarone, was associated with a significantly reduced risk of CAD. Conclusion We found that the use of allopurinol and benzbromarone, whether alone or in combination, had a linear dose-response relationship between the numbers of defined daily doses and the risk of CAD, especially in higher DDDs.

Original languageEnglish
Pages (from-to)85-90
Number of pages6
JournalInternational Journal of Cardiology
Volume233
DOIs
Publication statusPublished - Apr 15 2017

Fingerprint

Gout
Coronary Disease
Coronary Artery Disease
Benzbromarone
Population
Allopurinol
Drug Dose Response Relationship
Age Factors
Incidence
National Health Programs
benzbromarone drug combination allopurinol
Hyperlipidemias
Taiwan
Chronic Renal Insufficiency
Pharmaceutical Preparations
Medical Records
Diabetes Mellitus
Myocardial Infarction
Databases
Hypertension

Keywords

  • Anti-hyperuricemic drugs
  • Coronary artery disease
  • Dose-effect
  • Gout
  • Risk

ASJC Scopus subject areas

  • Medicine(all)
  • Cardiology and Cardiovascular Medicine

Cite this

Allopurinol, benzbromarone and risk of coronary heart disease in gout patients : A population-based study. / Lin, Hsiu Chen; Daimon, Masao; Wang, Ching Hung; Ho, Yi; Uang, Yow Shieng; Chiang, Shuo Ju; Wang, Li Hsuan.

In: International Journal of Cardiology, Vol. 233, 15.04.2017, p. 85-90.

Research output: Contribution to journalArticle

@article{69530ef1e08b4f1cab11d6e0bce36281,
title = "Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study",
abstract = "Background The effect of gout on the risk of developing coronary artery disease (CAD) is uncertain. Some studies have found that gout is a risk factor for acute myocardial infarction. This study examined the changes in risk of CAD in gout patients taking allopurinol and/or benzbromarone, and analyzed the dose-response relationship of both drugs with CAD incidence. Methods The medical records of one million subjects from 2000 to 2011 were provided by the Taiwan National Health Insurance Research Database. Cox proportional hazard ratio was used to compare the risk of CAD in gout patients taking allopurinol or/and benzbromarone with those taking neither drug. Hazard ratios (HR) were adjusted for possible confounding factors, including age, gender, hypertension, hyperlipidemia, diabetes mellitus, chronic kidney disease, and relevant medications. Results Of 8047 gout patients, 1422 were treated with allopurinol (Group A), 4141 with benzbromarone (Group B), and 2484 with both drugs (Group A/B) during the follow-up period. Our results showed the incidence of CAD after adjusting for covariates for Group A, Group B, and Group A/B did not significantly differ from the comparison group. However, after adjustment for covariates in dose-response analyses, treatment with over 270 defined daily doses (DDDs) of allopurinol, and over 360 DDDs of benzbromarone, was associated with a significantly reduced risk of CAD. Conclusion We found that the use of allopurinol and benzbromarone, whether alone or in combination, had a linear dose-response relationship between the numbers of defined daily doses and the risk of CAD, especially in higher DDDs.",
keywords = "Anti-hyperuricemic drugs, Coronary artery disease, Dose-effect, Gout, Risk",
author = "Lin, {Hsiu Chen} and Masao Daimon and Wang, {Ching Hung} and Yi Ho and Uang, {Yow Shieng} and Chiang, {Shuo Ju} and Wang, {Li Hsuan}",
year = "2017",
month = "4",
day = "15",
doi = "10.1016/j.ijcard.2017.02.013",
language = "English",
volume = "233",
pages = "85--90",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Allopurinol, benzbromarone and risk of coronary heart disease in gout patients

T2 - A population-based study

AU - Lin, Hsiu Chen

AU - Daimon, Masao

AU - Wang, Ching Hung

AU - Ho, Yi

AU - Uang, Yow Shieng

AU - Chiang, Shuo Ju

AU - Wang, Li Hsuan

PY - 2017/4/15

Y1 - 2017/4/15

N2 - Background The effect of gout on the risk of developing coronary artery disease (CAD) is uncertain. Some studies have found that gout is a risk factor for acute myocardial infarction. This study examined the changes in risk of CAD in gout patients taking allopurinol and/or benzbromarone, and analyzed the dose-response relationship of both drugs with CAD incidence. Methods The medical records of one million subjects from 2000 to 2011 were provided by the Taiwan National Health Insurance Research Database. Cox proportional hazard ratio was used to compare the risk of CAD in gout patients taking allopurinol or/and benzbromarone with those taking neither drug. Hazard ratios (HR) were adjusted for possible confounding factors, including age, gender, hypertension, hyperlipidemia, diabetes mellitus, chronic kidney disease, and relevant medications. Results Of 8047 gout patients, 1422 were treated with allopurinol (Group A), 4141 with benzbromarone (Group B), and 2484 with both drugs (Group A/B) during the follow-up period. Our results showed the incidence of CAD after adjusting for covariates for Group A, Group B, and Group A/B did not significantly differ from the comparison group. However, after adjustment for covariates in dose-response analyses, treatment with over 270 defined daily doses (DDDs) of allopurinol, and over 360 DDDs of benzbromarone, was associated with a significantly reduced risk of CAD. Conclusion We found that the use of allopurinol and benzbromarone, whether alone or in combination, had a linear dose-response relationship between the numbers of defined daily doses and the risk of CAD, especially in higher DDDs.

AB - Background The effect of gout on the risk of developing coronary artery disease (CAD) is uncertain. Some studies have found that gout is a risk factor for acute myocardial infarction. This study examined the changes in risk of CAD in gout patients taking allopurinol and/or benzbromarone, and analyzed the dose-response relationship of both drugs with CAD incidence. Methods The medical records of one million subjects from 2000 to 2011 were provided by the Taiwan National Health Insurance Research Database. Cox proportional hazard ratio was used to compare the risk of CAD in gout patients taking allopurinol or/and benzbromarone with those taking neither drug. Hazard ratios (HR) were adjusted for possible confounding factors, including age, gender, hypertension, hyperlipidemia, diabetes mellitus, chronic kidney disease, and relevant medications. Results Of 8047 gout patients, 1422 were treated with allopurinol (Group A), 4141 with benzbromarone (Group B), and 2484 with both drugs (Group A/B) during the follow-up period. Our results showed the incidence of CAD after adjusting for covariates for Group A, Group B, and Group A/B did not significantly differ from the comparison group. However, after adjustment for covariates in dose-response analyses, treatment with over 270 defined daily doses (DDDs) of allopurinol, and over 360 DDDs of benzbromarone, was associated with a significantly reduced risk of CAD. Conclusion We found that the use of allopurinol and benzbromarone, whether alone or in combination, had a linear dose-response relationship between the numbers of defined daily doses and the risk of CAD, especially in higher DDDs.

KW - Anti-hyperuricemic drugs

KW - Coronary artery disease

KW - Dose-effect

KW - Gout

KW - Risk

UR - http://www.scopus.com/inward/record.url?scp=85011949860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011949860&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2017.02.013

DO - 10.1016/j.ijcard.2017.02.013

M3 - Article

VL - 233

SP - 85

EP - 90

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -